We are live on ! Find out more
CHNA

Loncar China BioPharma ETF
CHNA

Delisted

CHNA was delisted on the 20th of October, 2023.

Back to rankings

4 hedge funds and large institutions have $920K invested in Loncar China BioPharma ETF in 2021 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

11.03% less ownership

Funds ownership: 17.26% → 6.23% (-11%)

43% less funds holding

Funds holding: 7 → 4 (-3)

57% less capital invested

Capital invested by funds: $2.13M → $920K (-$1.22M)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
4
Holders Change
-3
Holders Change %
-42.86%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$48.1K
2
Morgan Stanley
Morgan Stanley
New York
+$7.01K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$3.73K

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$761K
2
Citadel Advisors
Citadel Advisors
Florida
-$346K
3
FEM
Fulcrum Equity Management
Texas
-$326K
4
Osaic Holdings
Osaic Holdings
Arizona
-$23K

CHNA Hedge Fund Activity: Q1 2021 in Review

4 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q1 2021, worth a combined $920K — down 57% from $2.13M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of CHNA and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was UBS Group, adding an estimated $48.1K. The largest seller was Jane Street, cutting an estimated $761K.

  • 4 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q1 2021, down from 7 in Q4 2020.
  • Funds reported $920K of Loncar China BioPharma ETF stock for Q1 2021, down 57% quarter-over-quarter.
  • 1 fund opened new Loncar China BioPharma ETF positions in Q1 2021 and 3 closed out, a net change of -2 holders.
  • The largest Loncar China BioPharma ETF buyer in Q1 2021 was UBS Group, an estimated $48.1K added.
  • The largest Loncar China BioPharma ETF seller in Q1 2021 was Jane Street, an estimated $761K sold.

Based on aggregated 13F filings for Q1 2021.